Sponsor & Developer Portfolio

Sanofi

Clinical development pipeline, platform architecture, and registered trial tracking for Sanofi vaccine candidates.

31
Candidates
15
Target Diseases
38
Linked Studies

Development Phase Distribution

Discontinued / Inactive: 13 Phase 2 Clinical Trial: 8 Phase 3 Clinical Trial: 7 Phase 1 Clinical Trial: 3

Platform Technologies

Biological (unspecified platform): 13 Conjugate vaccine: 7 mRNA: 5 Protein / subunit: 3 Inactivated: 2 Toxoid: 1

Target Pathogens & Indications

Acne COVID-19 Chlamydia Trachomatis Immunization Clostridium Difficile Infection Dengue Genital Herpes HIV Influenza Melanoma Meningococcal disease Pneumococcal disease RSV RSV / hMPV / PIV3 Smallpox Yellow fever

Vaccine Pipeline Candidates (31)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

Discontinued / Inactive ctgov-acam1000-sanofi-pasteur-a-sanofi-company

ACAM1000

Target: Smallpox

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2003-03 (registry estimate)
Discontinued / Inactive ctgov-alvac-2-melanoma-multi-antigen-therapeutic-vaccine-sanofi-pasteu

ALVAC(2) melanoma multi-antigen therapeutic vaccine

Target: Melanoma

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2010-04 (registry estimate)
Discontinued / Inactive ctgov-c-difficile-toxoid-vaccine-sanofi-pasteur-a-sanofi-company

C. difficile Toxoid Vaccine

Target: Clostridium Difficile Infection

Platform: Toxoid

Key Milestone: Primary completion (most advanced trial): 2018-06-12 (registry estimate)
Discontinued / Inactive ctgov-cyd-dengue-vaccine-sanofi-pasteur-a-sanofi-company

CYD Dengue Vaccine

Target: Dengue

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2019-12-10 (registry estimate)
Discontinued / Inactive ctgov-hsv-2-formulation-1-sanofi-pasteur-a-sanofi-company

HSV 2 Formulation 1

Target: Genital Herpes

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2021-05-19 (registry estimate)
Discontinued / Inactive ctgov-mva-smallpox-vaccine-sanofi-pasteur-a-sanofi-company

MVA Smallpox Vaccine

Target: HIV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2007-07 (registry estimate)
Discontinued / Inactive ctgov-meningococcal-polysaccharide-diphtheria-toxoid-conjugate-sanofi-

Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2004-04 (registry estimate)
Discontinued / Inactive ctgov-quadrivalent-influenza-vaccine-split-virion-inactivated-high-dos

Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)

Target: Influenza

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2020-05-31 (registry estimate)
Discontinued / Inactive ctgov-quadrivalent-influenza-vaccine-high-dose-sanofi-pasteur-a-sanofi

Quadrivalent influenza vaccine, high-dose

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2021-06-02 (registry estimate)
Discontinued / Inactive ctgov-recombinant-influenza-vaccine-riv4-sanofi-pasteur-a-sanofi-compa

Recombinant influenza vaccine (RIV4)

Target: Influenza

Platform: Protein / subunit

Key Milestone: Primary completion (most advanced trial): 2023-10-03 (registry estimate)
Discontinued / Inactive ctgov-vaccine-diluent-buffer-sanofi

Sanofi Clostridium difficile toxoid vaccine

Target: Clostridium Difficile Infection

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2006-06 (registry estimate)
Discontinued / Inactive ctgov-sars-cov-2-mrna-vaccine-formulation-1-sanofi-pasteur-a-sanofi-co

Sanofi SARS-CoV-2 mRNA vaccine (first-in-human formulation)

Target: COVID-19

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2022-06-27 (registry estimate)
Discontinued / Inactive ctgov-trivalent-inactivated-influenza-vaccine-high-dose-sanofi

Trivalent inactivated influenza vaccine

Target: Influenza

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2011-05 (registry estimate)
Phase 1 Clinical Trial ctgov-h5-flu-investigational-medical-product-imp-1-sanofi

H5 Flu IMP 2

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-04-04 (registry estimate)
Phase 1 Clinical Trial ctgov-vxb-241-60-mcg-low-dose-sanofi

VXB-241 240 mcg

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2025-02-14 (registry estimate)
Phase 1 Clinical Trial ctgov-trivalent-rsv-hmpv-piv3-vaccine-candidate-sanofi

VXB-251 (RSV/hMPV/PIV3 trivalent vaccine)

Target: RSV / hMPV / PIV3

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-04-21 (registry estimate)
Phase 2 Clinical Trial ctgov-acne-mrna-vaccine-sanofi-pasteur-a-sanofi-company

Acne mRNA vaccine

Target: Acne

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2029-06-19 (registry estimate)
Phase 2 Clinical Trial ctgov-chlamydia-mrna-vaccine-sanofi

Chlamydia mRNA Vaccine

Target: Chlamydia Trachomatis Immunization

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2028-01-03 (registry estimate)
Phase 2 Clinical Trial ctgov-flu-h5-egg-pandemic-low-dose-vaccine-with-adjuvant-sanofi

Flu H5 egg pandemic low dose vaccine, with adjuvant

Target: Influenza

Platform: Protein / subunit

Key Milestone: Primary completion (most advanced trial): 2028-02-22 (registry estimate)
Phase 2 Clinical Trial ctgov-investigational-hmpv-rsv-vaccine-sanofi-pasteur-a-sanofi-company

Licensed RSV Vaccine

Target: RSV

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2027-01-18 (registry estimate)
Phase 2 Clinical Trial ctgov-pentavalent-meningococcal-abcyw-vaccine-sanofi-pasteur-a-sanofi-

MenACYW conjugate vaccine

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2027-05-17 (registry estimate)
Phase 2 Clinical Trial ctgov-pandemic-flu-h5-ha-mrna-sd2-vaccine-sanofi

Pandemic flu H5 HA mRNA SD2 vaccine

Target: Influenza

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-12-01 (registry estimate)
Phase 2 Clinical Trial ctgov-rsv-hmpv-vaccine-sanofi

RSV+HMPV vaccine

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-05-03 (registry estimate)
Phase 2 Clinical Trial ctgov-yellow-fever-vaccine-produced-on-serum-free-vero-cells-sanofi-pa

Yellow fever vaccine

Target: Yellow fever

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2022-05-23 (registry estimate)
Phase 3 Clinical Trial ctgov-menacyw-conjugate-vaccine-sanofi

MenAC conjugate vaccine

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2026-05-01 (registry estimate)
Phase 3 Clinical Trial ctgov-menquadfi-meningococcal-polysaccharide-serogroups-a-c-w-and-y-te

MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur I

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2028-03-13 (registry estimate)
Phase 3 Clinical Trial ctgov-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxo

Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2023-03-09 (registry estimate)
Phase 3 Clinical Trial ctgov-omicron-subvariant-based-sars-cov-2-recombinant-spike-vaccine-ad

Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M

Target: COVID-19

Platform: Protein / subunit

Key Milestone: Primary completion (most advanced trial): 2026-11-26 (registry estimate)
Phase 3 Clinical Trial ctgov-pcv21-sanofi

PCV21

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2027-01-07 (registry estimate)
Phase 3 Clinical Trial ctgov-pcv21-vaccine-sanofi

Sanofi PCV21 (21-valent pneumococcal conjugate vaccine)

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2027-09-10 (registry estimate)
Phase 3 Clinical Trial ctgov-yellow-fever-vaccine-live-sanofi

Yellow fever vaccine (live)

Target: Yellow fever

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-11-28 (registry estimate)

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →